Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
1. A method of increasing or maintaining mitochondrial function, comprising:
administering to a subject in need thereof an effective amount of a urolithin, thereby increasing or maintaining mitochondrial function.
2. A method of treating, preventing, or managing a mitochondria-related disease or condition associated with altered mitochondrial function or a reduced mitochondrial density, comprising:
administering to a subject in need thereof a therapeutically effective amount of a urolithin, thereby treating, preventing, or managing the disease or condition associated with altered mitochondrial function or reduced mitochondrial density.
3. The method of claim 1 , wherein the urolithin is urolithin A.
4. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.
5. The method of claim 1 , wherein the urolithin is administered orally.
6. The method of claim 1 , wherein the urolithin is administered topically.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 3 , wherein the subject is a human.
9. The method of claim 2 , wherein the mitochondria-related disease or condition is selected from the group consisting of obesity, reduced metabolic rate, metabolic syndrome, diabetes mellitus, cardiovascular disease, hyperlipidemia, neurodegenerative disease, cognitive disorder, mood disorder, stress, and anxiety disorder.
10. The method of claim 2 , wherein the mitochondria-related disease or condition is decrease of muscle performance or mental performance.
11. The method of claim 2 , wherein the mitochondria-related disease or condition is an age-related decline in mitochondrial function.
12. The method of claim 2 , wherein the mitochondria-related disease or condition is an inherited disease.
13. The method of claim 2 , wherein the urolithin is urolithin A.
14. The method of claim 2 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.
15. The method of claim 2 , wherein the urolithin is administered orally.
16. The method of claim 2 , wherein the urolithin is administered topically.
17. The method of claim 2 , wherein the subject is a human.
18. The method of claim 13 , wherein the subject is a human.
19. The method of claim 1 , wherein the urolithin is administered parenterally.
20. The method of claim 2 , wherein the urolithin is administered parenterally.
21. The method of claim 1 , wherein mitochondrial function is maintained.
22. The method of claim 1 , wherein mitochondrial function is increased.
23. The method of claim 1 , wherein mitochondrial activity is increased.
24. The method of claim 2 , wherein mitochondrial activity is increased.
25. The method of claim 1 , wherein the energy of the subject is increased.
26. The method of claim 1 , wherein mitochondrial biogenesis is increased.
27. The method of claim 2 , wherein mitochondrial biogenesis is increased.
28. The method of claim 1 , wherein ATP levels are increased in a tissue.
29. The method of claim 28 , wherein the tissue is a muscle tissue.
30. The method of claim 2 , wherein ATP levels are increased in a tissue.
31. The method of claim 30 , wherein the tissue is a muscle tissue.
32. The method of claim 1 , wherein the urolithin is administered intraveneously.
33. The method of claim 2 , wherein the urolithin is administered intraveneously.